MDST Medicsight

 

TIDMMDST 
 
RNS Number : 5690Z 
Medicsight Plc 
24 September 2009 
 

 
+------------------------------------+------------------------------------+ 
| Press Release                      |                  24 September 2009 | 
+------------------------------------+------------------------------------+ 
 
 
Medicsight Plc 
("Medicsight" or "the Company") 
MedicRead(TM) 3.0 Colon granted Canadian approval 
 
 
Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided 
Detection (CAD) and image analysis software which assists in the early detection 
and diagnosis of disease, announces that it has received approval from the 
Therapeutic Products Directorate (TPD) of Health Canada to market its 
MedicRead(TM) 3.0 Colon advanced 3D visualisation workstation, incorporating 
ColonCAD(TM) 4.0 software. 
 
 
Previously, access to Medicsight's ColonCAD has been available via a number of 
partner visualisation platforms. Now, as part of its ongoing commitment to 
radiologists and to improving the early detection of colorectal cancers, 
Medicsight has developed MedicRead 3.0 Colon, a competitively priced, 
stand-alone, CTC visualisation workstation that incorporates the latest version 
of Medicsight's ColonCAD 4.0. To aid access to this latest software, Medicsight 
has made MedicRead 3.0 Colon available online, with a 30-day free trial version 
of the software available via the Medicsight website (1). 
 
 
Allan Rowley, Chief Executive of Medicsight, commented: "Canada is one of the 
fastest growing multi-slice detector CT (MDCT) markets in the world. This 
approval will give Medicsight direct access to the radiology departments in many 
of the 450 hospitals and clinics across Canada and they can now benefit from the 
Company's latest advances in CAD technology and CT image analysis software". 
 
 
This year an estimated 22,000 Canadians (12,100 men - 9,900 women) will be 
diagnosed with colorectal cancer (2). If diagnosed and treated in its early 
stages, colorectal cancer is highly treatable. Routine screening tests that 
detect polyps before they become cancerous can reduce the number of people who 
die of colorectal cancer by as much as 60% (3). 
 
Medicsight recently also received medical device licenses from the Therapeutic 
Products Directorate of Health Canada for its MedicServer(TM) 1.1 application 
which includes Medicsight's industry-leading ColonCAD(TM) 4.0 API and 
LungCAD(TM) 3.2 API  software.  MedicServer(TM) is a unique server-based 
Windows  application, which has been specifically designed to optimise workflow 
through centralised pre-processing of CT scan data. 
 
 
Dr Tanya Chawla, Assistant Professor of Abdominal Imaging, Department of Imaging 
at Mount Sinai Hospital, Toronto commented: "The approval of MedicRead 3.0 Colon 
offers radiologists access to a cost effective CTC stand-alone workstation that 
incorporates the latest version of ColonCAD. This is exciting because it 
facilitates the performance of CT-colonography in radiology departments. It is 
also an invaluable teaching tool and may be used as a second reader in the 
appropriate setting." 
 
 
ColonCAD 4.0 marks a significant increase in performance from the previous 
version, displaying a 50% reduction in false positives without any significant 
loss in sensitivity (4). This significantly enhances the contribution CAD can 
make to workflow in busy radiology departments, compared with earlier versions. 
 
 
Early detection of polyps can significantly improve chances of preventing 
disease progression and Medicsight's CAD technology analyses CT scan data and 
automatically highlights potential lesions for the radiologist to review. These 
lesions could be the early precursors of potential life-threatening disease. 
 
 
References 
1.  Subject to local regulatory approval. 
2. Statistics Canada (www.statcan.gc.ca). 
3. Smith RA, Mettlin CJ, Eyre H. 31. Cancer Screening and Early Detection. In: 
D.W. Kufe et al., eds. Cancer Medicine. 6 ed. Hamilton, London: BC Decker Inc, 
2003 
4.  Data on file Medicsight PLC 2009. 
 
 
- ENDS - 
 
 
  For further information: 
 
 
+-------------------------------------------+----------------------------+ 
| Medicsight PLC                            | www.medicsight.com         | 
+-------------------------------------------+----------------------------+ 
| Allan Rowley                              | +44 (0)20 7605 7950        | 
|                                           |                            | 
+-------------------------------------------+----------------------------+ 
| Daniel Stewart & Company PLC              |                            | 
+-------------------------------------------+----------------------------+ 
| Simon Leathers                            | +44 (0) 20 7776 6550       | 
+-------------------------------------------+----------------------------+ 
Media enquiries: 
+-------------------------------------------+----------------------------+ 
| Abchurch                                  | +44 (0) 20 7398 7700       | 
+-------------------------------------------+----------------------------+ 
| Heather Salmond / Stephanie Cuthbert /    | +44 (0) 20 7398 7718       | 
| Simone Alves                              |                            | 
+-------------------------------------------+----------------------------+ 
| stephanie.cuthbert@abchurch-group.com     | www.abchurch-group.com     | 
+-------------------------------------------+----------------------------+ 
 
 
Notes to editors 
Medicsight PLC is a UK-headquartered, research driven, leading developer of 
computer-aided detection (CAD) and image analysis software for the medical 
imaging market. The CAD software automatically highlights suspicious areas on 
computerised tomography (CT) scans of the colon and lung, 
helping radiologists to identify, measure and analyse potential disease and 
early indicators of disease. Medicsight's CAD software has been validated using 
one of the world's largest and most population diverse databases of verified 
patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software 
products are seamlessly integrated with the advanced 3D visualisation 
workstations of several industry-leading imaging equipment partners. 
 
 
About Computer-Aided Detection 
With increasingly sophisticated radiological imaging hardware such as 
Multi-Detector CT scanners, radiologists are facing a growing challenge in the 
amount of detailed patient image data that they must review for each patient 
examination. Some CT scan examinations generate as many as 1000 images per 
patient. Review of this data by the radiologist is not only time-consuming but 
also prone to error due to reader fatigue. CAD software can help the reviewing 
radiologist by analysing the image data and automatically highlighting 
suspicious regions of interest for closer inspection. Without CAD software some 
potential abnormalities or areas of disease may be overlooked. This is critical 
for diagnosis and the management of patient outcomes as early detection of 
disease greatly increases the probability of successful treatment and a positive 
therapeutic outcome. 
 
 
About Medicsight's CAD software 
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm 
to analyse CT scans of the colon and lung and automatically highlight suspicious 
areas that may be indicators of disease. CAD may highlight areas easily 
overlooked by the reviewing radiologist, such as small lesions or regions that 
are hidden from view behind folds in the colon or normal structures and 
surrounding tissue in the lung. 
 
 
Both CAD products seamlessly integrate with the advanced 3D visualisation 
platforms of industry-leading imaging equipment partners. The integrated systems 
provide sophisticated image viewing capabilities, including 3D reconstructed 
image data, with the added advantage of demonstrating automatic CAD findings to 
assist clinical end users in the detection and analysis of disease. This allows 
clinical end users to perform either a 'second read', where CAD findings are 
displayed to the user after completion of an initial review of the CT scan data, 
or a 'concurrent read' where CAD findings are displayed during the user's 
initial review of the original CT scan images. 
 
 
Since inception, Medicsight has developed close and lasting relationships with 
some of the world's foremost clinicians in product related areas. This provides 
the Company with a wealth of clinical expertise and dedicated clinical research 
to support ongoing product development. Medicsight also collaborates with a 
number of leading academic institutions and clinical research programmes 
worldwide to develop the Company's comprehensive database of population diverse 
verified patient CT scan data, thus allowing Medicsight's products to be 
validated to the highest possible standards. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCLJMFTMMJTBBL 
 

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024